Brooks Laboratories Limited — Board Meeting, 29-05-2026: Outcome of Board Meeting

Brooks Labs Board approved Q4 & FY26 results. Consolidated PAT for FY26 hit ₹24.58 Cr, with Q4 PAT at ₹1.52 Cr. The company will continue to focus exclusively on its core pharmaceutical operations. Prashant Rathi was appointed CEO, adding to his CFO responsibilities.